PROTECT AGAINST PNEUMOCOCCAL PNEUMONIA

PROTECT AGAINST PNEUMOCOCCAL PNEUMONIA

About PCV20

Vaccination can help protect against pneumococcal disease.1

Proven condifence
The 20-valent pneumococcal conjugate vaccine (PCV20) is Pfizer’s latest-generation vaccine, covering up to 20 serotypes for broader protection.It can be administered starting at 6 weeks of age, and for individuals aged 2 years or older, only a single dose is required—currently the only option that does not require additional pneumococcal vaccines.†Pfizer has over 20 years of experience in pneumococcal vaccine research and immunization*, with more than 300 million doses administered worldwide,^ reinforcing its strong safety profile and trusted confidence. 2-4, 14-15
PCV20 legacy timeline

Percentage of paediatrics IPD cases potentially
covered by vaccine serotypes in different countries(2014-2022) 5-10

Worldwide paed IPD case

The above data sources cover different years and age groups; for details, please refer to the original data websites

Percentage of adult IPD cases potentially
covered by vaccine serotypes in different countries(2014-2019) 5,6,10-13

Worldwide adult IPD case

The above data sources cover different years and age groups; for details, please refer to the original data websites

Talk to your doctor

Talk to your
doctor

All pneumococcal vaccines are prescription medicines. Efficacy and side effects may vary among individuals due to different physical conditions and symptoms. Please consult your doctor or pharmacist for details.

References

  1. National Foundation for Infectious Diseases. What is pneumococcal disease? Available at: www.nfid.org/infectious-disease/pneumococcal/. Accessed Oct 2025.
  2. Ho PL, et al. Diagn Microbiol Infect Dis 2011;71:327-334.
  3. Drug Office. Search drugs database. Available at: www.drugoffice.gov.hk/eps/drug/productDetail/en/pharmaceutical_trade/138577. Accessed Oct 2025.
  4. Chapman R, et al. Vaccine 2020;38:7138-7145.
  5. CHP. Report on IPD. Available at: https://www.chp.gov.hk/en/resources/29/636.html Accessed Oct 2025.
  6. Ladhani SN, et al. Lancet Infect Dis 2018;18:441-451.
  7. Simell B, et al. Clin Infect Dis 2022;76:e1062-e1070.
  8. Dipartimento Malattie Infettive, Istituto Superiore di Sanità. Sorveglianza delle malattie batteriche invasive in Italia, Rapporto Consolidato 2018. Available at: www.iss.it/documents/20126/0/Rapporto+consolidato+MIB+2019.pdf/1faeb457-9859-4809-bf8a-4eaf405937c1?t=1621576238. Accessed Dec 2024.
  9. Kim SH, et al. Ann Lab Med 2023;43:45-48.
  10. Ubukata K, et al. Emerg Infect Dis 2018;24:2010-2020.
  11. Silva-Costa C, et al. Microorganisms 2021;9:1016.
  12. Dipartimento Malattie Infettive, Istituto Superiore di Sanità. Sorveglianza delle malattie batteriche invasive in Italia, Rapporto Consolidato 2019. Available at: www.iss.it/documents/20126/0/Rapporto+consolidato+MIB+2019.pdf/1faeb457-9859-f800-b9aa-bf8aea405093?t=1612517562338. Accessed Oct 2025.
  13. Kim GR, et al. Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Causing Invasive Pneumococcal Disease in Korea Between 2017 and 2019 After Introduction of the 13-Valent Pneumococcal Conjugate Vaccine. Ann Lab Med 2023;43:45-54. https://doi.org/10.3343/alm.2023.43.1.45 Accessed Oct 2025
  14. CHP. Frequently Asked Questions. Available at: https://www.chp.gov.hk/en/features/100770.html Accessed Oct 2025
  15. CDC. Pneumococcal Vaccine Timing for Adults. Available at: https://www.cdc.gov/pneumococcal/downloads/Vaccine-Timing-Adults-JobAid.pdf Accessed Oct 2025